Evidence map›Paper›PMID 39314240›Full record

ArticleiScience2024

β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease.

Jacob A Torres, Nickolas Holznecht, David A Asplund, Bradley C Kroes, Tselmeg Amarlkhagva, Matthias M Haeffner, Elizabeth H Sharpe, Stella Koestner, Sebastian Strubl, Margaret F Schimmel and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jacob A TorresDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Nickolas HolznechtDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
David A AsplundDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Bradley C KroesDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Tselmeg AmarlkhagvaDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Matthias M HaeffnerDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Elizabeth H SharpeDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Stella KoestnerDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Sebastian StrublDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Margaret F SchimmelDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Samantha KrugerDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Shagun AgrawalDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Brina A AcevesDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.
Muthusamy ThangarajuDepartment of Biochemistry and Molecular Biology, University of Augusta, Augusta, GA, USA.
Thomas WeimbsDepartment of Molecular, Cellular, Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.

Funding

Ketosis as a therapy for polycystic kidney diseaseR01DK124895 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI WEIMBS, THOMAS · 2020 to 2024
$2.2M
Role of renal crystal deposition in the progression of polycystic kidney diseaseR01DK109563 · NIDDK · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI WEIMBS, THOMAS · 2017 to 2020
$1.4M
NIDDK NIH HHS R01 DK109563NIDDK NIH HHS R01 DK124895
6 · The paper itself

Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) is a common monogenic disease characterized by the formation of fluid-filled renal cysts, loss of mitochondrial function, decreased fatty acid oxidation, increased glycolysis, and likely renal failure. We previously demonstrated that inducing a state of ketosis ameliorates or reverses PKD progression in multiple animal models. In this study, we compare time-restricted feeding and 48-h periodic fasting regimens in both juvenile and adult Cy/+ rats. Both fasting regimens potently prevent juvenile disease progression and partially reverse PKD in adults. To explore the mechanism of fasting, we administered β-hydroxybutyrate (BHB) to Cy/+ rats and orthologous mouse models of PKD (

Indexed as

DietPathophysiologyTherapy

Identifiers

PMID39314240
PMCPMC11418134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.